Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helicase eIF4A with zotatifin, the first-in-class eIF4A inhibitor, exerts pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic triple-negative breast cancer (TNBC) mouse models. Zotatifin not only suppresses tumor cell proliferation but also directly repolarizes macrophages toward an M1-like phenotype and inhibits neutrophil infiltration, which sensitizes tumors to immune checkpoint blockade. Mechanistic studies revealed that zotatifin reprograms the tumor translational landscape, inhibits the translation of Sox4 and Fgfr1, and induces an interferon (IFN) response uniformly across models. The induction of an IFN response is partially due to the inhibition of Sox4 translation by zotatifin. A similar induction of IFN-stimulated genes was observed in breast cancer patient biopsies following zotatifin treatment. Surprisingly, zotatifin significantly synergizes with carboplatin to trigger DNA damage and an even heightened IFN response, resulting in T cell-dependent tumor suppression. These studies identified a vulnerability of eIF4A in TNBC, potential pharmacodynamic biomarkers for zotatifin, and provide a rationale for new combination regimens consisting of zotatifin and chemotherapy or immunotherapy as treatments for TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“eIF4A inhibitors, which target both isoforms, suppress translation of key oncogenes and have demonstrated antitumor activity in a variety of cancers (15, 17, 19–22).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, eIF4A1 is essential for embryonic development in mice (18) and in various cancer cell lines (19), whereas eIF4A2 is not.”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270 · cited 8×
“In summary, strategies to augment ICB and chemotherapy are needed for TNBC treatment.”
InfluentialMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Yunna, C., Mengru, H., Lei, W., & Weidong, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173090 · Cited by 2,454 · cited 2×
“…effect is not due to a nonspecific stress response, as zotatifin did not increase the phosphorylation of eIF2 α , an integrated stress response marker, nor M1-like tumor-inhibitory phenotype (35), zotatifin treatment increased the percentage of iNOS + cells as compared with the vehicle (Figure 2G).”
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711 · cited 1×
“Recent improvements have also been made in treating metastatic TNBC with an anti-body-drug conjugate (4) or ICB in combination with chemotherapy in PD-L1 + TNBC (5, 6).”
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Ryckman, C., Vandal, K., Rouleau, P., Talbot, M., & Tessier, P. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3233 · Cited by 858
CXC chemokines in angiogenesis
Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., Burdick, M. D., & Strieter, R. M. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.1.1 · Cited by 804
Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1010 · Cited by 711
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
Self-citationProteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy
Krug, K., Jaehnig, E. J., Satpathy, S., Blumenberg, L., Karpova, A., Anurag, M., Miles, G., Mertins, P., Geffen, Y., Tang, L. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.036 · Cited by 537
Self-citationHollern, D. P., Xu, N., Thennavan, A., Glodowski, C., Garcia-Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 478
Self-citationSurvival analysis and regression models
George, B., Seals, S., & Aban, I. (2014) · Journal of Nuclear Cardiology · doi:10.1007/s12350-014-9908-2 · Cited by 473
Blasius, A. L., Giurisato, E., Cella, M., Schreiber, R. D., Shaw, A. S., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3260 · Cited by 437
Transcriptional Control of Macrophage Polarization
Tugal, D., Liao, X., & Jain, M. K. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301453 · Cited by 399
An NK-like CAR T cell transition in CAR T cell dysfunction
Good, C. R., Aznar, M. A., Kuramitsu, S., Samareh, P., Agarwal, S., Donahue, G., Ishiyama, K., Wellhausen, N., Rennels, A. K., Ma, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.016 · Cited by 396
Dempster, J. M., Boyle, I., Vazquez, F., Root, D. E., Boehm, J. S., Hahn, W. C., Tsherniak, A., & McFarland, J. M. (2021) · Genome Biology · doi:10.1186/s13059-021-02540-7 · Cited by 393
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378
Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A
Bordeleau, M.-E., Mori, A., Oberer, M., Lindqvist, L., Chard, L. S., Higa, T., Belsham, G. J., Wagner, G., Tanaka, J., & Pelletier, J. (2006) · Nature Chemical Biology · doi:10.1038/nchembio776 · Cited by 366
Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34753 · Cited by 332
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 327
Self-citationRocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
Iwasaki, S., Floor, S. N., & Ingolia, N. T. (2016) · Nature · doi:10.1038/nature17978 · Cited by 313
Erratum: New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.30 · Cited by 303
Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
The plasticity of mRNA translation during cancer progression and therapy resistance
Fabbri, L., Chakraborty, A., Robert, C., & Vagner, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00380-y · Cited by 276
The Organizing Principles of Eukaryotic Ribosome Recruitment
Pelletier, J., & Sonenberg, N. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111042 · Cited by 271
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y.-X. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 269
Pfefferle, A. D., Herschkowitz, J. I., Usary, J., Harrell, J. C., Spike, B. T., Adams, J. R., Torres-Arzayus, M. I., Brown, M., Egan, S. E., Wahl, G. M., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-11-r125 · Cited by 224
Self-citationIntegrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer
Bagati, A., Kumar, S., Jiang, P., Pyrdol, J., Zou, A. E., Godicelj, A., Mathewson, N. D., Cartwright, A. N. R., Cejas, P., Brown, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.001 · Cited by 215
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells
Herschkowitz, J. I., Zhao, W., Zhang, M., Usary, J., Murrow, G., Edwards, D., Knezevic, J., Greene, S. B., Darr, D., Troester, M. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018862108 · Cited by 209
Self-citationA mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development
Jerry, D. J., Kittrell, F. S., Kuperwasser, C., Laucirica, R., Dickinson, E. S., Bonilla, P. J., Butel, J. S., & Medina, D. (2000) · Oncogene · doi:10.1038/sj.onc.1203270 · Cited by 204
Rubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200
Tekpli, X., Lien, T., Røssevold, A. H., Nebdal, D., Borgen, E., Ohnstad, H. O., Kyte, J. A., Vallon-Christersson, J., Fongaard, M., Due, E. U., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13329-5 · Cited by 192
How cancer cells make and respond to interferon-I
Cheon, H., Wang, Y., Wightman, S. M., Jackson, M. W., & Stark, G. R. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.09.003 · Cited by 192
The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA
Iwasaki, S., Iwasaki, W., Takahashi, M., Sakamoto, A., Watanabe, C., Shichino, Y., Floor, S. N., Fujiwara, K., Mito, M., Dodo, K., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.026 · Cited by 190
The helicase Ded1p controls use of near-cognate translation initiation codons in 5′ UTRs
Guenther, U.-P., Weinberg, D. E., Zubradt, M. M., Tedeschi, F. A., Stawicki, B. N., Zagore, L. L., Brar, G. A., Licatalosi, D. D., Bartel, D. P., Weissman, J. S., et al. (2018) · Nature · doi:10.1038/s41586-018-0258-0 · Cited by 172
Salvagno, C., Ciampricotti, M., Tuit, S., Hau, C.-S., van Weverwijk, A., Coffelt, S. B., Kersten, K., Vrijland, K., Kos, K., Ulas, T., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0298-1 · Cited by 168
Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00182 · Cited by 150 · cited 3×
“To further explore whether the observed effects of zotatifin are through targeting eIF4A1, we employed HAP1 cells that express a mutant eIF4A1 (F163L) generated through CRISPR/Cas9-mediated gene editing (23).”
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Anurag, M., Jaehnig, E. J., Krug, K., Lei, J. T., Bergstrom, E. J., Kim, B.-J., Vashist, T. D., Huynh, A. M. T., Dou, Y., Gou, X., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0200 · Cited by 147
Self-citationEvidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex
Sadlish, H., Galicia-Vazquez, G., Paris, C. G., Aust, T., Bhullar, B., Chang, L., Helliwell, S. B., Hoepfner, D., Knapp, B., Riedl, R., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400158t · Cited by 127
Müller, E., Speth, M., Christopoulos, P. F., Lunde, A., Avdagic, A., Øynebråten, I., & Corthay, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02520 · Cited by 115
eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13086-5 · Cited by 106
Moreira-Teixeira, L., Sousa, J., McNab, F. W., Torrado, E., Cardoso, F., Machado, H., Castro, F., Cardoso, V., Gaifem, J., Wu, X., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600584 · Cited by 99
Chu, J., Galicia-Vázquez, G., Cencic, R., Mills, J. R., Katigbak, A., Porco, J. A., & Pelletier, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.005 · Cited by 95
Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis
Lin, C.-J., Nasr, Z., Premsrirut, P. K., Porco, J. A., Hippo, Y., Lowe, S. W., & Pelletier, J. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.010 · Cited by 90
Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A
Chen, M., Asanuma, M., Takahashi, M., Shichino, Y., Mito, M., Fujiwara, K., Saito, H., Floor, S. N., Ingolia, N. T., Sodeoka, M., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.11.008 · Cited by 82
Polysome Profiling Analysis of mRNA and Associated Proteins Engaged in Translation
Pringle, E. S., McCormick, C., & Cheng, Z. (2019) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.79 · Cited by 81
Singh, S., Lee, N., Pedroza, D. A., Bado, I., Hamor, C., Zhang, L., Aguirre, S., Hu, J., Shen, Y., Xu, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3714 · Cited by 71
Self-citationRocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F
Chu, J., Zhang, W., Cencic, R., O’Connor, P. B. F., Robert, F., Devine, W. G., Selznick, A., Henkel, T. O., Merrick, W. C., Brown, L. E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.002 · Cited by 70
Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A
Cencic, R., & Pelletier, J. (2016) · Translation · doi:10.1080/21690731.2015.1137381 · Cited by 62
Gerson‐Gurwitz, A., Young, N. P., Goel, V., Eam, B., Stumpf, C. R., Chen, J. W., Fish, S., Barrera, M., Sung, E., Staunton, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766298 · Cited by 51
Roarty, K. P., Pfefferle, A. D., Creighton, C. J., Perou, C. M., & Rosen, J. M. (2017) · Oncogene · doi:10.1038/onc.2017.206 · Cited by 47
Self-citationMüller, D., Shin, S., Goullet de Rugy, T., Samain, R., Baer, R., Strehaiano, M., Masvidal-Sanz, L., Guillermet-Guibert, J., Jean, C., Tsukumo, Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.121951 · Cited by 43
Pfefferle, A. D., Agrawal, Y., Koboldt, D. C., Kanchi, K., Herschkowitz, J. I., Mardis, E. R., Rosen, J. M., & Perou, C. M. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025239 · Cited by 36
Self-citationChatterjee, S., Yabaji, S. M., Rukhlenko, O. S., Bhattacharya, B., Waligurski, E., Vallavoju, N., Ray, S., Kholodenko, B. Ν., Brown, L. E., Beeler, A. B., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102845 · Cited by 33
Ho, J. J. D., Cunningham, T. A., Manara, P., Coughlin, C. A., Arumov, A., Roberts, E. R., Osteen, A., Kumar, P., Bilbao, D., Krieger, J. R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109806 · Cited by 30
Nguyen, T. M., Kabotyanski, E. B., Dou, Y., Reineke, L. C., Zhang, P., Zhang, X. H.-F., Malovannaya, A., Jung, S. Y., Mo, Q., Roarty, K. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0631 · Cited by 25
Self-citationRosen, E. Y., Sharma, M. R., Berz, D., Caswell-Jin, J. L., Spira, A. I., Fulgar, G. A., Densel, M., Rana, N., Sperry, S., Warner, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.1080 · Cited by 20
Schiffmann, S., Henke, M., Seifert, M., Ulshöfer, T., Roser, L. A., Magari, F., Wendel, H., Grünweller, A., & Parnham, M. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065872 · Cited by 10
Cited by
Cencic, R., Im, Y. K., Naineni, S. K., Moustafa-Kamal, M., Jovanovic, P., Sabourin, V., Annis, M. G., Robert, F., Schmeing, T. M., Koromilas, A. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318093121 · Cited by 32
Pastena, P., Perera, H., Martinino, A., Kartsonis, W., & Giovinazzo, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052559 · Cited by 27
Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Lizardo, M. M., Hughes, C. S., Huang, Y. Z., Shyp, T., Delaidelli, A., Zhang, H., Shaool, S. S., Renner, A. F., Burwag, F., Sayles, L. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1317 · Cited by 20
Yuan, X., Hao, X., Chan, H. L., Zhao, N., Pedroza, D. A., Liu, F., Le, K., Smith, A. J., Calderon, S. J., Lieu, N., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.182621 · Cited by 18
Self-citationBoyer, J. A., Rosen, E. Y., Sharma, M., Dorso, M. A., Mai, N., Amor, C., Reiter, J., Kannan, R., Gadal, S., Xu, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2424286122 · Cited by 20
Metadata
- Authors
- Zhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., Smith, A. J., Hamor, C., Safari, K., Savage, S., Zhang, B., Zhou, J., Solis, L. M., Hilsenbeck, S. G., Fan, C., Perou, C. M., & Rosen, J. M.
- Affiliations
- Baylor College of Medicine (US)
- Texas A&M Health Science Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Rosen, Jeffrey M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2023-12-15
- Volume
- 133
- Issue
- 24
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10721161
- OpenAlex
- W4387909059
- Cited by
- 30
- References
- 68
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 10
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- NIH (CA16303-46)
- CPRIT (RP220468)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- eIF4A, triple-negative breast cancer, mRNA translation inhibition, interferon response, tumor immune microenvironment, macrophage polarization, neutrophil infiltration, immune checkpoint blockade, FGFR1, carboplatin, combination therapy, pharmacodynamic biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Interferons, Cell Line, Tumor, Cell Proliferation, Mice, Tumor Microenvironment, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.